-

SOLVD Health Launches 5-Year Post-Approval Study on Real-World Impact for AvertD® Genetic Test

Nationwide study to demonstrate long-term predictive accuracy of AvertD® in clinical setting

SAN DIEGO--(BUSINESS WIRE)--SOLVD Health (SOLVD), a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has launched a comprehensive post-approval study for AvertD®, the first U.S. Food and Drug Administration (FDA)-approved genetic test for assessing risk of developing opioid use disorder (OUD). This post-approval study aims to expand upon pivotal study findings and further demonstrate AvertD’s ability to enhance personalized data-driven decisions in real-world settings.

The prospective study will enroll up to 4,000 patients, integrating agile methods to gather comprehensive, real-world data from diverse demographic groups across the United States. Designed to confirm AvertD’s predictive accuracy across diverse populations, the study seeks to equip providers with critical insights for individualized, evidence-based pain management.

"The launch of our post-approval study for AvertD represents more than our commitment to regulatory requirements. It's a commitment to addressing one of the most pressing public health challenges of our time," said SOLVD Health Founder and CEO Dr. Keri Donaldson. “Every day, healthcare providers and their patients face challenging decisions about pain management. Our goal is to arm them with precise, personalized insights to guide these critical decisions and improve patient outcomes.”

The study will follow participants for up to five years, providing additional long-term data on the predictive value of genetic testing in OUD risk assessment. The extended timeframe will enable researchers to observe how genetic risk factors interact with environmental and behavioral influences over time, potentially uncovering new strategies for addiction prevention and intervention.

About SOLVD Health

SOLVD Health is a privately held company focused on preventing disease by making contextual health information accessible to everyone. Through the development of insights-based health tools, SOLVD Health enables individuals and their providers to make better decisions about their health and the health of their families. SOLVD Health accomplishes this by translating complex biological signals into actionable patient data that can point the way to better health. To learn more about SOLVD Health, its solutions, and career opportunities, visit www.solvdhealth.com.

Contacts

Media:
Valerie Melucci
Vice President of Marketing, SOLVD Health
pr@solvdhealth.com

Investors:
Mark Hazeltine
Chief Financial Officer, SOLVD Health
investors@solvdhealth.com

SOLVD Health


Release Versions

Contacts

Media:
Valerie Melucci
Vice President of Marketing, SOLVD Health
pr@solvdhealth.com

Investors:
Mark Hazeltine
Chief Financial Officer, SOLVD Health
investors@solvdhealth.com

More News From SOLVD Health

SOLVD Health’s Pharmacogenomics Test Receives New York State Department of Health Approval

SAN DIEGO--(BUSINESS WIRE)--SOLVD Health, a patient intelligence company pioneering precision medicine through advanced genetics and AI-driven insights, announced today that its pharmacogenomics (PGx) test PreScript™ has received approval from the New York State Department of Health’s Clinical Laboratory Evaluation Program (CLEP). This milestone enables SOLVD Health to offer its PGx testing services to healthcare providers and patients across New York State, one of the most rigorously regulated...

SOLVD Health Publishes Peer-Reviewed Framework to Advance Clinical Use of Genomic Data

SAN DIEGO--(BUSINESS WIRE)--SOLVD Health, a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has published a peer-reviewed article in the International Journal of Molecular Sciences on best practices for the clinical use of genome-wide association study (GWAS) data. The article provides guidance for integrating imputed genetic information into healthcare in a way that supports accuracy, transparency, and clinical utility. Co-authored by...

SOLVD Health Advances Development of Novel Test to Optimize GLP-1 Therapeutic Response

SAN DIEGO--(BUSINESS WIRE)--SOLVD Health, a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, today announced the launch of two studies to validate its innovative GLP-1 patient stratification diagnostic platform. These studies aim to transform obesity and type 2 diabetes care by enabling healthcare providers to identify individuals most likely to benefit from GLP-1 therapies, optimizing treatment outcomes and reducing unnecessary costs....
Back to Newsroom